newsfilter
← Latest News
ACCESS Newswire·

Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. , a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1